Telomir Pharmaceuticals Inc. – Material Contracts Watch

from 8-K 3 pages 1. Funding Commitment Upon Ind Acceptance the Participating Shareholder Acknowledges Their Intention to Support the Continued Development of Telomir-1 (Telomir-Zn) And, in Connection Therewith, May Provide to Telomir an Aggregate Amount of Two Million U.S. Dollars (US $2,000,000), in the Form of Either Cash or Marketable Securities (Valued at the Time of Transfer), Promptly Following the U.S. Food and Drug Administration’s Acceptance of an Investigational New Drug (Ind) Application for Telomir-1 (The “Initial Funding Commitment”) in Exchange for 1,492,537 Shares of Common Stock of the Company, or $2,000,000 Divided by $1.34, or the Closing Price on the NASDAQ Stock Exchange of the Company’s Common Stock on April 15, 2026 (The “Initial Shares”)

from 8-K 16 pages Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan

from 8-K 3 pages Binding Letter of Intent

from 8-K 3 pages Re: Employment Letter Agreement Dear Mr. Weichselbaum: Telomir Pharmaceuticals, Inc. (The “Company”) Is Pleased to Offer You Employment on the Following Terms. Subject to Any Pre-Employment Requirements, Your Employment Will Commence on May 19, 2025 (The “Start Date”) or Such Other Date as You and the Company May Agree

from 10-Q 7 pages Employment Agreement

from 8-K 5 pages Employment Agreement

from S-1/A 4 pages Debt Conversion Agreement

from S-1/A 4 pages Debt Conversion Agreement

from S-1/A ~5 pages Agreement for Shared Lease Costs

from S-1/A 7 pages First Amended and Restated Employment Agreement

from S-1/A 11 pages Indemnification Agreement

from S-1/A 5 pages Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan Stock Option Award

from S-1/A 19 pages Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan

from S-1 7 pages Employment Agreement

from S-1 6 pages Employment Agreement

from S-1 2 pages Amendment No. 1 to Amended & Restated Exclusive License Agreement

from S-1 9 pages Amended & Restated Exclusive License Agreement